The Role of 5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|31|5069-5076

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.31, 2014-09, pp. : 5069-5076

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists

By  

Current Pharmaceutical Design, Vol. 16, Iss. 3, 2010-01 ,pp. : 309-322

Bentham Science Publishers

Access to resources Recommend Favorite

Adrenergic targets for the treatment of cognitive deficits in schizophrenia

By Arnsten Amy  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

The quest for the treatment of cognitive impairment: α7 nicotinic and α5 GABAA receptor modulators

By Romanelli Maria Novella   Gualtieri Fulvio  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 11, 2007-11 ,pp. : 1365-1377

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Cognitive Deficits Associated with Schizophrenia: Potential Role of Catechol-O-Methyltransferase Inhibitors

By Apud José A.   Weinberger Daniel R.  

CNS Drugs, Vol. 21, Iss. 7, 2007-01 ,pp. : 535-557

Adis International

Access to resources Recommend Favorite

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

By Geerts Hugo  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 59-65

Informa Healthcare

Access to resources Recommend Favorite